Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010
   Trial
2. Ten-year follow-up outcomes of resected stage II non-small cell lung cancer patients.Journal of thoracic disease · 2025
   Article
3. Alectinib impressively enters the adjuvant setting for early-stageTranslational lung cancer research · 2025
   Article
4. Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.Molecular diagnosis & therapy · 2019
   Article
5. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.Journal of cancer research and clinical oncology · 2014
   Article
6. High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer.Oncology letters · 2013
   Article
7. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.Journal of experimental & clinical cancer research : CR · 2011
   Review
8. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011
   Article

Corrections and comments

• Comment on
  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.2008

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as